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Background: Microglia are considered the “resident macrophages” of the brain. When in their resting state,
microglia perform routine maintenance and immune surveillance. Once activated, either by injury or an immune
stimulus, microglia secrete a variety of pro-inflammatory molecules, such as Nitric Oxide, superoxide, and
inflammatory cytokines. Up-regulation of pro-inflammatory molecules is transient, and does not cause
neurodegeneration. However, if up-regulation lasts for an extended period of time, neurodegeneration ensues.
Many neurodegenerative diseases are characterized by chronic inflammation due to microglial activation. Non-
Steroidal Anti-Inflammatory Drugs (NSAIDs) have been proposed as possible preventative treatments for
neurodegenerative diseases, due to their anti-inflammatory properties. Docosahexaenoic Acid (DHA) is an omega-3
polyunsaturated fatty acid (PUFA) that has potent anti-inflammatory properties.This research work sought to
elucidate whether microglial activation can be modulated by combining Aspirin, a classical NSAID, with
Docosahexaenoic Acid, a natural anti-inflammatory agent. The combined ability of Aspirin and DHA to modulate
microglial activation was determined in the context of pro-inflammatory cytokines, Nitric Oxide levels, as well as
total Glutathione levels.
Results: Docosahexaenoic Acid increased total Glutathione levels in microglia cells and enhanced their anti-
oxidative capacity. It reduced production of the pro-inflammatory cytokines TNF-α and IL-6 induced through TLR-3
and TLR-4 activation. Furthermore, it reduced production of Nitric Oxide. Aspirin showed similar anti-inflammatory
effects with respect to TNF-α during TLR-3 and TLR-7 stimulation. Aspirin did not show any redection in terms of
Nitric Oxide production. Combination of Aspirin and Docosahexaenoic Acid showed augmentation in total
Glutathione production during TLR-7 stimulation as well as a reduction in IL-6, TNF-α and Nitric Oxide.
Conclusions: Collectively, these findings highlight the combination of Docosahexaenoic Acid and Aspirin as a
possible measure against inflammation of the nervous system, thus leading to protection against
neurodegenerative diseases with an inflammatory etiology.
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Neurodegeneration is defined as the loss of the structure
and function of neurons [1]. Neurodegeneration due to
microglial activation and inflammation is seen in many
Central Nervous System (CNS) pathologies, especially
neurodegenerative diseases (ND) [2,3]. NDs that involve
neurodegeneration include Alzheimer’s disease (AD),* Correspondence: evassili@kean.edu
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reproduction in any medium, provided the orAmyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis
(MS), and Parkinson’s disease (PD) [1,4]. Although these
diseases are characterized by neurodegeneration, they
differ in the area of the brain that is affected, leading to
the different pathologies that exist for each type of ND
[1]. In Alzheimer’s disease, chronic inflammation causes
neuronal cell death in the areas of the hippocampus and
frontal cortex [4]. Inflammation destroys motor neurons
in the spinal cord, brain stem, and cortex in Amyo-
trophic Lateral Sclerosis [4,5]. In Parkinson’s disease,
chronic inflammation causes the loss of dopaminergictd. This is an Open Access article distributed under the terms of the Creative
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Sclerosis is an autoimmune disorder where inflammatory
cells attack the myelin sheath that surrounds the axons
of neurons [4].
The brain is separated from the periphery by the blood
brain barrier, which allows the brain to be immuno-
priviledged [4]. Inflammation is an activated immune
state and is considered a normal self-defense mechanism
that is implemented by the body in order to fight patho-
gens [4]. Inflammation in the body recruits immune cells
to the area that is under attack, which will then clear the
system of the antigen [4]. When inflammation occurs in
the CNS, microglia are recruited to the affected area [4].
Microglia are considered the “resident macrophage” of
the brain [2,4]. When in their resting state, microglia
perform routine maintenance and immune surveillance
[4,5]. Once activated, either by injury or an immune
stimulus, microglia secrete a variety of pro-inflammatory
molecules, such as Nitric Oxide (NO), superoxide,
inflammatory cytokines, reactive oxygen species (ROS),
and glutamate [2-6]. Activated microglia also express
inducible Nitric Oxide synthase (iNOS), as well as cyclo-
oxygenase-2 (COX-2), which cause the production and
subsequent release of NO and pro-inflammatory cyto-
kines [7]. Neuronal cell death will not occur if the
inflammatory response is transient [4]. However, if a
prolonged inflammatory response occurs, chronic
inflammation, neurodegeneration and neuronal cell
death will also occur [2,4]. Neuronal cell death leads to
reactive microgliosis, the activation of microglia as a re-
sult of neuronal death [2]. Reactive microgliosis is toxic
to surrounding neurons and results in continued micro-
glial activation, inflammation, and neuronal death [2].
Microglia can be activated in a number of ways, in-
cluding injury or immunological stimuli [3,4]. Microglial
activation, due to immunological stimuli, occurs through
a Toll-Like Receptor (TLR) pathways [8]. TLR pathways
are considered the first line of defense against viral and
bacterial pathogens [8]. Toll-like receptors are a family
of nine receptors (TLR1-9) that are found on the cell’s
plasma membrane and on the surface of endosomal vesi-
cles, which specifically recognize conserved pathogen-
associated molecular patterns (PAMPs) that recognize a
variety of pathogens (bacteria, viruses, parasites, yeast
and fungi) [8]. Microglial expression of TLRs is un-
detectable when in their resting state [8]. However, once
activated, microglia rapidly express a variety of toll-like
receptors (TLR1-9) at differing intesities [8]. It should be
noted that over stimulation of TLRs can result in
chronic inflammation, leading to many inflammatory
diseases [8].
Microglial TLRs can be activated by exogenous and
endogenous TLR ligands, including Lipopolysaccharide
(LPS) and Polyinosinic-Polycytidylic acid (Poly I:C) [8].LPS, an endotoxin found in gram-negative bacteria acti-
vates TLR-4 receptors expressed on microglia [2,8]. Poly I:
C activates TLR-3 receptors on microglia by mimicking
the viral double stranded RNA observed during viral repli-
cation [8]. When microglial TLRs are stimulated by LPS
or Poly I:C, signaling occurs and causing the production
and subsequent secretion of inflammatory molecules,
reactive oxygen species, and glutamate [8]. These mole-
cules are neurotoxic and cause neurodegeneration [8].
The extent of neurodegeneration that occurs depends on
the intensity and length of microglial activation [9].
Cytokines are secreted by immune cells under a va-
riety of conditions [4]. Cytokines regulate inflammatory
processes and are also key regulators of ND pathologies
[4]. As the brain ages, the blood–brain barrier becomes
compromised, leading to an increase in the synthesis of
pro-inflammatory cytokines such as IL-6, TNF-α and
IL-1β [4]. This causes continued microglial activation
and neuro-inflammation [4]. IL-6, TNF-α and IL-1β
induce expression of the cyclo-oxygenase 2 (COX-2)
enzyme. Over expression of COX-2 has been shown to
be involved in neuronal apoptosis [4]. TNF-α and IL-1β
have also been shown to influence synaptic transmission
in vitro [10]. TNF-α is also thought to cause neurode-
generation by silencing cell survival signals and activa-
ting caspase-dependent pathways [11]. TNF-α causes
glutamate release by activated microglia, leading to exci-
toneurotoxicity and neuronal damage [11]. Excessive
IL-6 and IL-1β have been identified as being neurotoxic
[10]. However, it is not known if IL-6 and IL-1β are
directly causing neurotoxicity, or it is mediated by other
molecules such as ROS or glutamate [10]. In regards
to specific neurodegenerative diseases, brains affected
by Alzheimer’s disease have increased levels of pro-
inflammatory cytokines [4]. Pro-inflammatory cytokines
have also been suspected of being able to determine
the extent of neurodegeneration that is seen in Multiple
Sclerosis [10].
Excessive NO production is associated with both acute
and chronic inflammation [12]. Neurons are very
susceptible to Nitric Oxide-induced death and very low
concentrations can cause extensive neuronal damage
and death [3,13]. Recent studies suggest that activated
microglia kill co-cultured neurons through a NO and
ROS-mediated mechanism [3]. Glutamate-mediated
excitotoxicity has also been implicated in causing neur-
onal injury and death [5]. The following mechanism for
Nitric Oxide and glutamate-mediated neuronal cell
death has been proposed: NO is released by activated
microglia and inhibits neuronal respiration, causing
glutamate to be released by neurons [3]. Glutamate then
binds to NMDA receptors present on neuronal cells,
causing an extreme calcium influx, and ultimately neu-
ronal cell death [3].
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neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease, and Amyotrophic Lateral Sclerosis
[4]. In Alzheimer’s disease, plaque formation and accu-
mulation lead to an inflammatory response that causes
the production of ROS, and cause oxidative damage to
surrounding neurons [4]. Plaque accumulation also
causes oxidative damage, which leads to mitochondrial
dysfunction [4]. Together, mitochondrial dysfunction
and oxidative damage can also cause amyloid aggrega-
tion and tau polymerization [14]. In Parkinson’s disease,
increases in the generation of reactive oxygen species, as
well as lipid peroxidation, are seen in the substantia
nigra [4,14]. Lastly, the pathogenesis of familial and
sporadic Amyotrophic Lateral Sclerosis has been shown
to involve ROS and oxidative stress [4].
Recent studies suggest that Docosahexaenoic Acid
(DHA), a 22-carbon, long-chain polyunsaturated fatty
acid (LC-PUFA), could have beneficial effects in brain
diseases [15]. The combination of aspirin and DHA has
been shown to generate a number of anti-inflammatory
species [16]. DHA is a major fatty acid that makes up
about 12-16% of total fatty acids in the grey matter of
the brain [17]. DHA is important in proper brain deve-
lopment, and plays a role in maintaining a homeostatic
environment in the CNS [15,18,19]. DHA has been
shown to modulate important neurochemical processes,
synaptic plasticity, memory formation, neuroprotection,
gene expression, and intracellular calcium concentra-
tions [15,19]. DHA promotes neural stem cell differen-
tiation into neurons, as well as neurogenesis [15]. DHA
and its derivatives, whether made by peroxidation or
enzymatic processing, all have potent anti-inflammatory
properties in both acute and chronic ND [15]. DHA has
been shown to reduce the number of activated microglia
and reduce pro-inflammatory molecule production [15].
DHA is known for its anti-inflammatory properties
and has been shown to reduce pro-inflammatory cyto-
kine production in microglia [7,15]. The NF-κB signaling
pathway is important for mediating the expression
of genes such as COX-2 and iNOS, which encode
pro-inflammatory molecules, such as Nitric Oxide and
prostaglandins [7,12,20]. DHA inhibits pro-inflammatory
cytokine production by preventing NK-κB translocation
to the nucleus [12]. This causes a decrease in the tran-
scription of pro-inflammatory genes (COX-2 and iNOS)
[12]. Ultimately, pro-inflammatory cytokines and Nitric
Oxide production is reduced [12].
DHA also causes an increased level of intracellular
Glutathione (GSH), a potent antioxidant molecule that is
found in the brain at high concentrations [21]. High levels
of GSH have been shown to be important for suppressing
NF-κB activation [12]. Glutathione is also a cofactor for
Glutathione Peroxidase (GPx), an enzyme that convertshydrogen peroxide to water [12]. High expression of GPx
has been shown to inhibit the degredation of IκB, as well
as inhibit the activation of NF-κB [12]. Increased levels of
GSH, caused by DHA, enhance the activity of GPx, which
further inhibits the transcription and translation of
pro-inflammatory molecules through NF-κB signaling
[12]. DHA also increases the activity of Glutathione
Reductase (GR), an enzyme that is important in maintain-
ing the anti-oxidative capacity of cells by a GSH-based
mechanism [12,17]. In turn, the occurrence of up-
regulated GPx and GR in the brain causes an increase in
GSH, and an enhancement of the anti-oxidative defense
mechanism employed by the brain [12].
Nitric Oxide mediates inflammatory processes [13]. Re-
cently, DHA has been shown to reduce iNOS expression
and NO production in microglia [15]. DHA has also been
shown to inhibit iNOS expression and NO production in
murine macrophages [12]. DHA also down-regulates the
expression of genes involved in ROS production [22]. It is
thought that this reduction occurs through up-regulation
of the anti-oxidative capacity of the macrophages by
enhancing a Glutathione-mediated anti-oxidative mecha-
nism [12].
Dietary intake is the main source of DHA in humans
and when adequate, it offers visual, neurological and car-
diovascular health benefits [12-15,17,18]. Decreased
DHA intake can lead to oxidative damage, and has been
shown to cause cognitive insufficiencies and impaired
vision [4,18]. Reduced DHA intake in adults has been
shown to contribute to age-related cognitive deficiencies,
as well as neuronal dysfunction [15]. Low DHA in the
blood is hypothesized to be an important risk factor in
developing Alzheimer’s disease [17,23].
Increased dietary intake has been shown to signifi-
cantly alter DHA levels in the brain [17]. This suggests
that DHA supplementation could be used to directly
influence brain function [17]. Clinical studies suggest
dietary DHA supplementation can alter the risk of deve-
loping Alzheimer’s disease [17]. Participants with the
highest level of DHA in their blood also had a decreased
risk of developing dementia [17]. Moderate increases of
DHA in the daily diet have been shown to reduce the
risk of developing Alzheimer’s disease by 60% [24]. It
should be noted that elderly people who eat fish and sea-
food enriched with omega-3 PUFAs (i.e.: DHA) at least
once a week have a decreased risk of developing demen-
tia and Alzheimer’s disease [25]. The aforementioned
data suggests that DHA could be an effective therapy for
preventing Alzheimer’s disease, as well as other neurode-
generative diseases [25].
Non-steroidal anti-inflammatory drugs (NSAIDs) have
been proposed as a possible preventative treatment for
NDs [4]. NSAIDs, as their name describes, have anti-
inflammatory properties and can be selective for cyclo-
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the production of Nitric Oxide, as well as pro-inflammatory
cytokine production [26] NSAIDs that specifically target
COX-2 have been shown to reduce microglial activation,
block the production of pro-inflammatory cytokines, and
reduce the risk of Alzheimer’s disease [4]. NSAIDs have
also been shown to block the production and accumulation
of degenerative proteins, thereby reducing the risk of
Alzheimer’s disease [4]. NSAIDs that target COX-2 have
been shown to improve cognitive and motor functions in
mice [4,23]. Epidemiological studies have shown an inverse
relationship between NSAID intake and the development
of Alzheimer’s and Parkinson’s diseases [23,27]. NSAIDs
are also proposed to have an impact on the inflammatory
component of Multiple Sclerosis and Amyotrophic Lateral
Sclerosis [17]. Ibuprofen, a NSAID that is non-selective in
terms of COX-1 and COX2, has been proposed through
epidemiological studies as a possible preventative treatment
for Alzheimer’s disease [4]. However, Ibuprofen has
concerning side effects that have prevented it from being
used in clinical trials for Alzheimer’s prevention [4].
COX-2 in neurons, neurodegeneration caused by excito-
toxicity, as well as neurodegernation caused by microglia,
are proposed as the main targets of NSAIDs [23]. With
this information, classical NSAIDs are logically an attract-
ive option for delaying the onset and slowing the progres-
sion of neurodegenerative diseases [28]. Combination
therapies of different types of anti-inflammatory agents
are also proposed as a preventative therapy for neurode-
generative diseases because they can work through differ-
ent mechanisms [28].
This research project sought to elucidate whether
microglial activation can be modulated by combining
Aspirin, a classical NSAID, with Docosahexaenoic Acid,
a naturally occurring anti-inflammatory agent. The
combined ability of Aspirin and DHA to modulate acti-
vated microglia was determined in the context of pro-
inflammatory cytokines, Nitric Oxide levels, Reactive
Oxygen Species, as well as total Glutathione levels.
Results and discussion
Neither DHA pretreatment nor aspirin treatment cause
toxicity in activated microglia
EOC20 microglia were pretreated with DHA prior to
stimulation with TLR agonists, Aspirin treatment, or
combination. The MTT assay was used to determine if
DHA pretreatment, Aspirin treatment, or a combination
of both were toxic to EOC20 microglia. Absorbance
values of each treatment were compared to the
untreated group. Any treatment that had an absorbance
below the average absorbance for the untreated was
considered as toxic. Any treatment that had an absorb-
ance above the average absorbance for the untreated was
deemed non-toxic. DHA pretreatment did not causetoxicity (Figure 1A). Treatments with Aspirin at either
1mM or 5mM were also non-toxic (Figure 1A). DHA
pretreatment followed by 1mM Aspirin treatment was
not toxic (Figure 1A). However, DHA pretreatment and
5mM Aspirin treatment was slightly toxic (Figure 1A).
This toxicity was seen at 24 hours post Aspirin treat-
ment and causes some worry as to the amount of
toxicity that would be seen at 48 hours post Aspirin
treatment. For this reason, 1mM was chosen as the con-
centration of Aspirin to be used in future experiments.
Activation by Poly I:C (TLR-3) or Imiquimod (TLR-7)
were both non-toxic to EOC20 microglia at 24 hours
(Figure 1B-C). DHA pretreatment prior to TLR activa-
tion was not toxic to EOC20 microglia (Figure 1B-C).
Aspirin treatment at either 1mM or 5mM during TLR
activation was also not toxic (Figure 1B-C). A combin-
ation of DHA pretreatment and Aspirin treatment
(1mM or 5mM) was not toxic for either TLR-3 or TLR-7
activated microglia (Figure 1B-C).DHA pretreatment increases total Glutathione in
activated microglia
Microglia were activated with TLR agonists after a
24 hour pretreatment with DHA. The values were
normalized to the untreated. Results show that Poly I:C
and Imiquimod both cause a modest increase in total
Glutathione (8.5μM and 13μM, respectively; Figure 2).
These increases in Glutathione are significant (p < 0.05)
and indicate that both Poly I:C (TLR-3) and Imiquimod
(TLR-7) agonists can activate EOC20 microglia and
induce a Glutathione-based anti-oxidative mechanism.
When compared to TLR-3 and TLR-7 stimulations
where no DHA was present, DHA pretreatment signifi-
cantly increased total Glutathione (18.1μM and 56.8μM,
respectively) in both simulated viral infection environ-
ments (p < 0.05 and p < 0.0005, respectively; Figure 2).
This confirms that DHA can increase total Glutathione
and enhance the anti-oxidative capacity of activated
EOC20 microglia.DHA pretreatment plus aspirin increase total Glutathione
in activated microglia
EOC20 microglia were pretreated with DHA prior to
TLR stimulation, Aspirin treatment, or both. DHA
pretreatment, alone, increased total Glutathione produc-
tion to about 15μM (p < 0.005; Figure 3A). Aspirin
(1mM) treatment increased total Glutathione production
to 3.5μM (p < 0.05; Figure 3A). DHA pretreatment prior
to Aspirin (1mM) treatment increased total Glutathione
production to 15.6μM (Figure 3A). This increase in total
Glutathione is significant (p < 0.00005) when compared
to total Glutathione produced by 1mM Aspirin alone.
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Figure 1 A. 50,000 EOC20 Microglial Cells were plated in a 96 well plate containing Complete Medium plus 20% LADMAC Conditioned
Medium. Cells were stimulated with 50μM DHA for 24 hours. After 24 hours, cells were stimulated with either Aspirin at 1mM or Aspirin at 5mM.
At 24 hours post TLR stimulation and/or Aspirin treatment, the experimental plate was assayed for necrosis using a Non-Radioactive Cell
Proliferation kit (MTT Assay). Untrtd = Untreated; Asp1 = Aspirin (1mM); Asp5 = Aspirin (5mM); DHA = Docosahexaenoic Acid (50μM). * = p<0.05;
** = p<0.005. B. 50,000 EOC20 Microglia were plated in a 96 well plate containing Complete Medium plus 20% LADMAC Conditioned Medium.
Cells were stimulated with 50μM DHA for 24 hours. After 24 hours, cells were stimulated with Poly I:C, Aspirin at 1mM, Aspirin at 5mM, or a
combination of Poly I:C and Aspirin. At 24 hours post Poly I:C stimulation and/or Aspirin treatment, the experimental plate was assayed for
necrosis using a Non-Radioactive Cell Proliferation kit (MTT Assay). Untrtd = Untreated; PIC = Poly I:C (1μg/mL); Asp1 = Aspirin (1mM); Asp5 =
Aspirin (5mM); DHA = Docosahexaenoic Acid (50μM). * = p<0.05; ** = p<0.005; *** = p<0.0005. C. 50,000 EOC20 Microglia were plated in a 96
well plate containing Complete Medium plus 20% LADMAC Conditioned Medium. Cells were stimulated with 50μM DHA for 24 hours. After 24
hours, cells were stimulated with Imiquimod, Aspirin at 1mM, Aspirin at 5mM, or a combination of Imiquimod and Aspirin. At 24 hours post
Imiquimod stimulation and/or Aspirin treatment, the experimental plate was assayed for necrosis using a Non-Radioactive Cell Proliferation kit
(MTT Assay). Untrtd = Untreated; Imi = Imiquimod (10μg/mL); Asp1 = Aspirin (1mM); Asp5 = Aspirin (5mM); DHA = Docosahexaenoic Acid
(50μM). * = p<0.05; *** = p<0.0005; **** = p<0.00005; ***** = p<0.000005.
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ism in EOC20 microglia.
Poly I:C induced TLR-3 activation increased total
Glutathione production to 3.7μM (p < 0.05; Figure 3B).
Treatment with 1mM Aspirin during TLR-3 activation
increased total Glutathione production to 9.4μM (p < 0.005;
Figure 3B). DHA pretreatment prior to TLR-3 activation
and Aspirin (1mM) treatment further increased totalGlutathione production to 23.8μM (p < 0.005; Figure 3B).
The augmentation of total Glutathione in the presence of
DHA plus Aspirin and Poly I:C is noteworthy. This
synergism was not observed in the case of DHA, Aspirin
and Imiquimod.
Microglia activated by Imiquimod, a TLR-7 agonist,
produced 3.5μM total Glutathione (p < 0.005; Figure 3C).
Treatment with 1mM Aspirin during TLR-7 activation
Figure 2 50,000 EOC20 Microglia were plated in a 96 well plate
containing Complete Medium plus 20% LADMAC Conditioned
Medium. Cells were stimulated with 50μM DHA for 24 hours. After
24 hours, cells were stimulated with TLR agonists. At 24 hours post
TLR stimulation, supernatants and cellular extracts were collected;
total incubation time was 48 hours. Cellular extracts were assayed
for total Glutathione content. Values were normalized to the
untreated. Untrtd = Untreated; Imi = Imiquimod (10μg/mL);
PIC = Poly I:C (1μg/mL); DHA = Docosahexaenoic Acid (50μM).
*,# = p< 0.05; ** = p<0.005, ### = p<0.0005.
Pettit et al. Lipids in Health and Disease 2013, 12:16 Page 6 of 14
http://www.lipidworld.com/content/12/1/16increased total Glutathione production to 4.6μM (p < 0.1;
Figure 3C). Total Glutathione production was further
increased when EOC20 were pretreated with DHA prior
to TLR-7 activation and Aspirin (1mM) treatment
(13.6μM; p < 0.05; Figure 3C).
DHA pretreatment reduces Pro-inflammatory cytokine
secretion by activated microglia
EOC20 microglia were pretreated with DHA for
24 hours, and then stimulated with a TLR agonist. IL-6
secretion was measured using an IL-6 ELISA assay, and
values were normalized to the untreated. Results show
that DHA pretreatment does not induce baseline IL-6
production (Figure 4A). Activation with Poly I:C or Imi-
quimod both significantly increased IL-6 production
(p < 0.05, Figure 4A). Poly I:C caused secretion of
approximately 1200pg/mL of IL-6, whereas Imiquimod
resulted in approximately 600pg/mL (Figure 4A). This
indicates that Poly I:C (TLR-3 agonist) stimulation causes
a much more robust IL-6 response than Imiquimod.
When pre-treated with DHA prior to TLR stimulation, a
significant reduction on IL-6 secretion is seen. DHA caused
IL-6 secretion to be undetectable in EOC20 microglia acti-
vated by Poly I:C (p < 0.05, Figure 4A). This indicates that
DHA can effectively inhibit IL-6 pro-inflammatory cyto-
kine production in microglia activated by a TLR-3 agonist(Poly I:C). DHA pretreatment prior to Imiquimod (TLR-7)
activation caused IL-6 secretion to be significantly reduced
to 159pg/mL (p < 0.05; Figure 4A). This indicates that
DHA can also modulate IL-6 pro-inflammatory
cytokine production in EOC20 microglia activated by a
TLR-7 agonist.
EOC20 microglia were stimulated with a TLR-3 or
TLR-7 agonist after a 24 hour pretreatment with DHA.
TNF-α secretion was measured using a TNF-α ELISA,
and values were normalized to the untreated. Pretreat-
ment with DHA caused a low butd insignificant produc-
tion of baseline TNF-α (Figure 4B). Poly I:C and
Imiquimod both significantly increased TNF-α secretion
(80pg/mL and 150pg/mL, respectively; p < 0.05;
Figure 4B). This data shows that EOC20 microglial activa-
tion with Poly I:C (TLR-3) or Imiquimod (TLR-7) yields a
pro-inflammatory response that involves TNF-α, in
addition to IL-6.
When pre-treated with DHA for 24 hours prior to
TLR stimulation, TNF-α secretion was significantly
reduced (Figure 4B). DHA reduced TNF-α secretion by
Poly I:C activated microglia to 15pg/mL (p < 0.05;
Figure 4B). DHA pretreatment prior to Imiquimod
activation reduced TNF-α secretion to 76.5pg/mL
(p < 0.05; Figure 4B). This data suggests that DHA can
decrease TNF-α pro-inflammatory cytokine secretion by
EOC20 microglia that are activated by a TLR-3 or TLR-7
agonist.
Both sets of data indicate that DHA can effectively
exert its anti-inflammatory properties on microglia
that are activated by either a TLR-3 or TLR-7 agonist
(Poly I:C or Imiquimod, respectively).DHA pretreatment plus Aspirin cause Pro-inflammatory
cytokine production to be markedly reduced in activated
microglia
EOC20 microglia were pretreated with DHA prior to
TLR stimulation, Aspirin treatment, or both. IL-6
pro-inflammatory cytokine production was measured using
an IL-6 ELISA; values were normalized to the untreated.
Figures 5A-B show that Aspirin (1mM) treatment doesn’t
induce IL-6 production, as expected. DHA pretreatment
prior to Aspirin (1mM) treatment also doesn’t induce IL-6
production (Figure 5A-B). This indicates that neither
Aspirin treatment, nor DHA pretreatment prior to TLR
stimulation, affect baseline IL-6 production.
TLR-3 activation by Poly I:C significantly increased
IL-6 production to 305.9 pg/mL (p < 0.005; Figure 5A).
When treated with Aspirin (1mM) during TLR-3 activa-
tion, IL-6 secretion was reduced to 190.3pg/mL (p < 0.05;
Figure 5A). DHA pretreatment prior to TLR-3 activation
and Aspirin treatment further reduced IL-6 secretion by
activated microglia (77.11pg/mL; p < 0.005; Figure 5A).
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Figure 3 A. 50,000 EOC20 Microglia were plated in a 96 well plate containing Complete Medium plus 20% LADMAC Conditioned
Medium. Cells were stimulated with 50μM DHA for 24 hours. After 24 hours, cells were treated with 1mM Aspirin. At 24 hours post Aspirin
treatment, supernatants and cellular extracts were collected; total incubation time was 48 hours. Cellular extracts were assayed for total
Glutathione content. Values were normalized to the untreated. Untrtd = Untreated; Asp = Aspirin (1mM); DHA = Docosahexaenoic Acid (50μM).
* = p< 0.05; ** = p<0.005, #### = p<0.00005. 3B. 50,000 EOC20 Microglia were plated in a 96 well plate containing Complete Medium plus 20%
LADMAC Conditioned Medium. Cells were stimulated with 50μM DHA for 24 hours. After 24 hours, cells were treated with Poly I:C, 1mM Aspirin,
or a combination of Poly I:C and Aspirin. At 24 hours post Poly I:C and/or Aspirin treatment, supernatants and cellular extracts were collected;
total incubation time was 48 hours. Cellular extracts were assayed for total Glutathione content. Values were normalized to the untreated. Untrtd
= Untreated; PIC = Poly I:C (1μg/mL); Asp = Aspirin (1mM); DHA = Docosahexaenoic Acid (50μM). * = p<0.05; **,##,§§ = p<0.005. 3C. 50,000
EOC20 Microglia were plated in a 96 well plate containing Complete Medium plus 20% LADMAC Conditioned Medium. Cells were stimulated
with 50μM DHA for 24 hours. After 24 hours, cells were treated with Imiquimod, 1mM Aspirin, or a combination of Imiquimod and Aspirin. At 24
hours post Imiquimod and/or Aspirin treatment, supernatants and cellular extracts were collected; total incubation time was 48 hours. Cellular
extracts were assayed for total Glutathione content. Values were normalized to the untreated. Untrtd = Untreated; Imi = Imiquimod (10μg/mL);
Asp = Aspirin (1mM); DHA = Docosahexaenoic Acid (50μM). *,#,§ = p<0.05; ** = p<0.005.
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Figure 4 A. 50,000 EOC20 Microglia were plated in a 96 well plate containing Complete Medium plus 20% LADMAC Conditioned
Medium. Cells were stimulated with 50μM DHA for 24 hours. After 24 hours, cells were stimulated with TLR agonists. At 24 hours post TLR
stimulation, supernatants were collected; total incubation time was 48 hours. IL-6 secretion was determined by assaying the supernatants with an
IL-6 ELISA. Values were normalized to the untreated. Untrtd = Untreated; Imi = Imiquimod (10μg/mL); PIC = Poly I:C (1μg/mL); DHA =
Docosahexaenoic Acid (50μM). *,# = p< 0.05. 4B. 50,000 EOC20 Microglia were plated in a 96 well plate containing Complete Medium plus 20%
LADMAC Conditioned Medium. Cells were stimulated with 50μM DHA for 24 hours. After 24 hours, cells were stimulated with TLR agonists. At 24
hours post TLR stimulation, supernatants were collected; total incubation time was 48 hours. TNF- α secretion was determined by assaying the
supernatants with a TNF- α ELISA. Values were normalized to the untreated. Untrtd = Untreated; Imi = Imiquimod (10μg/mL);
PIC = Poly I:C (1μg/mL); DHA = Docosahexaenoic Acid (50μM). *,# = p< 0.05.
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secreted 1451.8pg/mL IL-6 (p < 0.0000006; Figure 5B).
When treated with Aspirin during TLR-7 activation,
IL-6 production was slightly increased (1574.14pg/mL;
Figure 5B). Aspirin’s inability to reduce production of IL-6
when the stimulus is a TLR-7 agonist (Imiquimod) is rather
surprising. Pretreatment with DHA prior to TLR-7 activa-
tion and Aspirin treatment significantly reduces IL-6
production to 757.9pg/mL (p < 0.0005; Figure 5B).
These results indicate that the presence of DHA prior to
TLR stimulation is very important when trying to reduce
IL-6 pro-inflammatory cytokine production in response to
TLR-3 or TLR-7 activation.
TNF-α pro-inflammatory cytokine production was mea-
sured with a TNF-α ELISA, and values were normalized to
the untreated. Figures 5C-D indicate that Aspirin (1mM)
treatment has no effect on TNF-α production. TNF-α is
also undetectable in EOC20 microglia cultures that were
pretreated with DHA prior to Aspirin (1mM) treatment
(Figure 5C-D). These results show that neither Aspirin
treatment, nor DHA pretreatment prior to Aspirin
treatment, affect baseline TNF-α production.
Poly I:C (TLR-3) stimulation caused a modest but
statistically significant production of TNF-α (5.0pg/mL;
p < 0.0005; Figure 5C). Treatment with 1mM Aspirin
during TLR-3 activation caused TNF-α to be undetect-
able (p < 0.005; Figure 5C). This indicates that Aspirinexerts anti-inflammatory properties during a TLR-3
simulated infectious environment. Pretreatment with
DHA prior to TLR-3 activation and Aspirin treatment
also caused TNF-α production to be undetectable
(p < 0.000005; Figure 5C).
TLR-7 activation by Imiquimod caused 747.8pg/mL of
TNF-α to be secreted by EOC20 microglia (p < 0.005;
Figure 5D). Treatment with 1mM Aspirin during
TLR-7 activation significantly reduced TNF-α production
to 385.9pg/mL (p < 0.05; Figure 5D). Pretreatment with
DHA prior to TLR-7 activation and Aspirin treatment
caused TNF-α production to be undetectable (p < 0.005;
Figure 5D).
When taken together, the results of the IL-6 and
TNF-α ELISAs suggest that DHA pre-treatment prior to
TLR activation is the most effective way to reduce pro-
inflammatory cytokine production. Furthermore, Aspirin
treatment can enhance the reduction in pro-inflammatory
cytokines with the notable exception of Imiquimod and IL-6.DHA pretreatment reduces total Nitric Oxide secreted by
activated microglia
Poly I:C and Imiquimod cause a significant increase in
Nitric Oxide in EOC20 microglia cells (15μM and
16.7μM, respectively; p < 0.005). This indicates that both
TLR-3 and TLR-7 activation of EOC20 microglia can
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Figure 5 A. 50,000 EOC20 Microglia were plated in a 96 well plate containing Complete Medium plus 20% LADMAC Conditioned
Medium. Cells were stimulated with 50μM DHA for 24 hours. After 24 hours, cells were stimulated with Poly I:C, 1mM Aspirin, or a combination
of Poly I:C and Aspirin. At 24 hours post Poly I:C and/or Aspirin treatment, supernatants were collected; total incubation time was 48 hours. IL-6
ELISAs determined IL-6 secretion. Values were normalized to the untreated. Untrtd = Untreated; PIC = Poly I:C (1μg/mL); Asp = Aspirin (1mM);
DHA = Docosahexaenoic Acid (50μM). # = p< 0.05; **,§§ = p<0.005. 5B. 50,000 EOC20 Microglia were plated in a 96 well plate containing
Complete Medium plus 20% LADMAC Conditioned Medium. Cells were stimulated with 50μM DHA for 24 hours. After 24 hours, cells were
stimulated with Imiquimod, 1mM Aspirin, or a combination of Imiquimod and Aspirin. At 24 hours post Imiquimod and/or Aspirin treatment,
supernatants were collected; total incubation time was 48 hours. IL-6 ELISAs determined IL-6 secretion. Values were normalized to the untreated.
Untrtd = Untreated; Imi = Imiquimod (10μg/mL); Asp = Aspirin (1mM); DHA = Docosahexaenoic Acid (50μM). §§§ = p<0.0005; #### = p<0.00005;
****** = p<0.0000005. 5C. 50,000 EOC20 Microglia were plated and stimulated as in 5A. TNF- α ELISAs determined TNF- α secretion. Values were
normalized to the untreated. Untrtd = Untreated; PIC = Poly I:C (1μg/mL); Asp = Aspirin (1mM); DHA = Docosahexaenoic Acid (50μM).
## = p< 0.005; *** = p< 0.0005; §§§§§ = p<0.000005. 5D. 50,000 EOC20 Microglia were plated and stimulated as in 5B. TNF- α ELISAs determined
TNF- α secretion. Values were normalized to the untreated. Untrtd = Untreated; Imi = Imiquimod (10μg/mL); Asp = Aspirin
(1mM)DHA = Docosahexaenoic Acid (50μM). # = p<0.05; **, §§ = p<0.005.
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Figure 6 50,000 EOC20 Microglia were plated in a 96 well plate
containing Complete Medium plus 20% LADMAC Conditioned
Medium. Cells were stimulated with 50μM DHA for 24 hours. After
24 hours, cells were stimulated with TLR agonists. At 24 hours post
TLR stimulation, supernatants were collected; total incubation time
was 48 hours. Supernatants were assayed for total Nitric Oxide
content using a total Nitric Oxide kit. Values were normalized to the
untreated. Untrtd = Untreated; Imi = Imiquimod (10μg/mL);
PIC = Poly I:C (1μg/mL); DHA = Docosahexaenoic Acid (50μM).
## = p<0.005; ***,### = p<0.0005.
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is partially mediated by Nitric Oxide.
DHA pretreatment prior to TLR-3 or TLR-7 activation
caused a significant decrease in Total Nitric Oxide
production. DHA pretreatment prior to Poly I:C stimu-
lation reduced total Nitric Oxide production to 11.95μM
(p < 0.005; Figure 6). Total Nitric Oxide was reduced to
12.74 μM when microglia were pretreated with DHA
prior to Imiquimod stimulation (p < 0.0005; Figure 6).
This suggests that DHA can reduce Nitric Oxide-based
inflammation and oxidative stress that occur in EOC20
microglia when activated by a TLR-3 or TLR-7 agonist.DHA pretreatment plus Aspirin cause total Nitric Oxide to
be undetectable in activated microglia
Pretreatment with DHA for 24 hours caused total Nitric
Oxide to be undetectable, indicating that DHA does not
induce baseline Nitric Oxide (p < 0.005; Figures 7A-B). This
result is also seen when EOC20 microglia are treated with
1mM Aspirin alone (p < 0.005; Figures 7A-B). Total Nitric
Oxide production was also undetectable in EOC20 micro-
glia that were pretreated with DHA prior to Aspirin (1mM)
treatment (p < 0.005; Figures 7A-B). This indicates that the
combined therapy of DHA pretreatment and Aspirin treat-
ment does not influence baseline Nitric Oxide production.Microglia activated by Poly I:C (TLR-3) produced
14.3μM total Nitric Oxide (p < 0.0005; Figure 7A). Treat-
ment with Aspirin (1mM) increased total Nitric Oxide
production by Poly I:C activated microglia (22.78μM;
Figure 7A). This increase in total Nitric Oxide was signifi-
cant (p < 0.005), indicating that 1mM Aspirin could be
augmenting Nitric Oxide production in TLR-3 activated
microglia, rather than reducing it. Total Nitric Oxide was
undetectable in TLR-3 activated microglia that were
pretreated with DHA prior to TLR-3 activation and Aspirin
treatment (p < 0.000005; Figure 7A).
TLR-7 activation by Imiquimod increased total Nitric
Oxide secretion to about 20μM (p < 0.005; Figure 7B).
Aspirin (1mM) increased total Nitric Oxide secretion by
TLR-7 activated microglia (24.1μM; Figure 7B). However,
this modest increase in total Nitric Oxide due to Aspirin
(1mM) treatment was not significant (p>0.1). Total Nitric
Oxide was undetectable in TLR-7 activated microglia that
were pretreated with DHA prior to TLR activation and
Aspirin treatment (p < 0.0005; Figure 7B).
Conclusions
Epidemiological studies show an inverse relationship
between NSAID intake and the development of Alzhei-
mer’s and Parkinson’s diseases [23,27]. NSAIDs
that specifically target COX-2 have been shown to
reduce microglia activation, block the production of
pro-inflammatory cytokines, and reduce the risk of
Alzheimer’s disease [4]. NSAIDs are also proposed to have
an effect on the inflammatory component of Multiple
Sclerosis and Amyotrophic Lateral Sclerosis [27]). DHA
plays a key role in proper brain development and in main-
taining a homeostatic environment in the CNS [15,18,19].
DHA has been shown to modulate important neurochem-
ical processes, synaptic plasticity, memory formation,
neuroprotection, gene expression, and intracellular cal-
cium concentrations [15,19]. DHA has also been shown to
promote neuronal stem cell differentiation into neurons,
as well as neurogenesis [15]. Increased dietary intake has
been shown to significantly alter DHA levels in the brain,
suggesting that DHA could be used as a way to directly
influence brain function [17]. DHA has potent anti-
inflammatory properties in both acute and chronic neuro-
degenerative diseases [15]. DHA has been shown to reduce
the number of activated microglia and reduce pro-
inflammatory molecule production [15]. Clinical studies
suggest dietary DHA supplementation can alter the risk of
developing Alzheimer’s disease [17].
Our findings indicate that DHA pretreatment enhances
total Glutathione production in activated microglia. This
suggests that DHA has the ability to increase the anti-
oxidative capacity of EOC20 microglia, allowing the cells
to combat oxidative stress that occurs as a result of activa-
tion. DHA pretreatment also significantly reduced IL-6
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Figure 7 A. 50,000 EOC20 Microglia were plated in a 96 well plate containing Complete Medium plus 20% LADMAC Conditioned
Medium. Cells were stimulated with 50μΜ aspirin or a combination of aspirin and Poly I:C. At 24 hours post Poly I:C and/or asprin treatment,
supernatants were collected; total incubation time was 48 hrs. Supernatants were assayed for total Nitric Oxide using a total Nitric Oxide kit.
Values were normalized to the untreated. Untrtrd=Untreated; PIC=Poly I:C (1μg/mL); Asp = Aspirin (1mM); DHA = Docosahexaenoic Acid (50μM).
**, ## = p<0.005; *** = p<0.0005; §§§§§ = p<0.00005. B. 50,000 EOC20 Microglia were plated in a 96 well plate containing Complete Medium
plus 20% LADMAC Conditioned Medium. Cells were stimulated with 50μM DHA for 24 hours. After 24 hours, cells were stimulated with
Imiquimod, 1mM Aspirin, or a combination of Imiquimod and Aspirin. At 24 hours post Imiquimod and/or Aspirin treatment, supernatants were
collected; total incubation time was 48 hours. Supernatants were assayed for total Nitric Oxide content using a total Nitric Oxide kit. Values were
normalized to the untreated. Untrtd = Untreated; Imi = Imiquimod (10μg/mL); Asp = Aspirin (1mM); DHA = Docosahexaenoic Acid (50μM).
** = p<0.005; §§§ = p<0.0005.
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both TLR-3 and TLR-7 microglia activation, proving that
DHA can exert its anti-inflammatory properties in both
types of simulated viral infections. Total Nitric Oxide was
also reduced when EOC20 were pretreated with DHA
prior to TLR activation. This suggests that DHA can re-
duce NO-based inflammation and oxidative stress that
occur in EOC20 microglia when activated by a TLR-3 or
TLR-7 agonist.
Aspirin treatment alone enhanced baseline tGSH produc-
tion, indicating that Aspirin can also influence the
anti-oxidative capacity of EOC20 microglia in similar
manner to DHA. When combined with DHA pretreat-
ment, a further increase in total Glutathione production
was observed. This indicates that DHA pretreatment prior
to Aspirin treatment may be necessary in order to further
enhance the Glutathione-based anti-oxidative mechanism
that is activated by Aspirin.
IL-6 production as a result of TLR-3 activation was
reduced when treated with Aspirin. This indicates that
Aspirin exerts its anti-inflammatory properties on TLR-3
activated EOC20 microglia. TNF-α production was
undetectable when treated with Aspirin during TLR-3
activation, indicating that Aspirin affects TNF-α production
much more than it affects IL-6 production. Aspirintreatment during TLR-7 activation slightly increased IL-6
production. This indicates that concurrent Aspirin
treatment and TLR-7 activation is rather ineffective
in modulating IL-6 production arising from a TLR-7
stimulus. However, Aspirin treatment did signifi-
cantly reduce TNF-α production by TLR-7 activated
microglia. This causes us to believe that Aspirin
does, in fact, affect TNF-α production much more
than it affects IL-6 production. DHA pretreatment
prior to either TLR-3 or TLR-7 activation and As-
pirin treatment significantly reduced IL-6 production,
indicating that DHA pretreatment is the most effective
way to reduce pro-inflammatory cytokine production in
activated microglia.
Aspirin treatment during TLR-3 activation caused a sig-
nificant increase in total Nitric Oxide. This raises the pos-
sibility that use of Aspirin as an anti-inflammatory
molecule during TLR-3 simulated viral infection is inef-
fective. An increase in total Nitric Oxide was also seen
when treated with Aspirin during TLR-7 induced micro-
glia activation. This increase in total Nitric Oxide was not
significant, therefore we do not suspect Aspirin as being
problematic during TLR-7 induced microglia activation.
When pretreated with DHA prior to TLR activation and
Aspirin treatment, total Nitric Oxide was undetectable,
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Nitric Oxide production.
Collectively, these findings highlight the combination
of DHA and Aspirin as a possible preventative measure
against neurodegenerative diseases. Animal model stu-
dies would prove valuable in determining the overall
effect of DHA plus Aspirin dietary supplements as a
means to prevent/delay the onset of neurodegenerative
diseases.Methods
Preparation of LADMAC conditioned medium
LADMAC cells were purchased from the American Type
Culture Collection (ATCC; Manassas, VA) and used to
produce conditioned medium. Briefly, LADMAC were
cultured in 175cm2 tissue culture flasks containing
complete medium comprised of 10% Fetal Bovine Serum
(FBS), 1% Antibiotic/Antimycotic (Penicillin-Streptomycin/
Amphotericin B), 0.5% Gentamycin, and Dulbecco’s
Modified Eagle Medium. Cells were grown to 100%
confluency and supernatants were transferred to a 50mL
tube and spun at 3000xg for 15 minutes. The supernatants
were then passed through a 0.22 micron filter to remove
any remaining cells. Supernatants were then stored
at −20C for future use.Preparation of EOC20 microglia cultures
EOC20 microglia were obtained from the ATCC
(Manassas, VA). EOC20 were cultured in a 25cm2 tissue
culture flask containing complete medium consisting of
10% Fetal Bovine Serum (FBS), 20% LADMAC Condi-
tioned Medium (as described above), 1% Antibiotic/
Antimycotic (Penicillin-Streptomycin/Amphotericin B),
0.5% Gentamycin, and Dulbecco’s Modified Eagle
Medium. Upon 100% confluency, EOC20 were cultured
in 96 well plates at 200,000cells/mL and 250μL/well,
giving a final cell concentration of 50,000cells/well. Two
separate experimental set ups were used.
Experimental Setup #1: Cells were pretreated with
50μM Docosahexaenoic Acid (DHA; Cayman Chemicals;
Ann Arbor, MI) for 24 hours. At 24 hours post DHA
pretreatment, EOC20 microglia were stimulated with ei-
ther 1μg/mL Polyinosinic-Polycytidylic acid (Poly I:C;
InvivoGen; San Diego, CA), a TLR-3 agonist that mimics
viral double stranded RNA, or 10μg/mL Imiquimod
(InvivoGen; San Diego, CA), a TLR-7 agonist that
mimics single stranded RNA. TLR stimulation was for
24 hours, leading to a total incubation time of 48 hours.
At the end of the 48 hours, supernatants were collected
and stored at −20C. The experimental plate was washed
with 1x Phosphate Buffered Saline (PBS). 100μL 5%
Metaphosphoric Acid (MPA) was added to each experi-
mental well, and the plate was frozen at −80C.Experimental Setup #2: Cells were pretreated with
50μM Docosahexaenoic Acid (DHA; Cayman Chemicals;
Ann Arbor, MI) for 24 hours. At 24 hours post DHA
pretreatment, EOC20 microglia were stimulated with
either 1μg/mL Polyinosinic-Polycytidylic acid (Poly I:C;
InvivoGen; San Diego, CA), 10μg/mL Imiquimod
(InvivoGen; San Diego, CA), 1mM Aspirin (Sigma-
Aldrich Chemicals; Saint Louis, MO), 5mM Aspirin, or
a combination of TLR agonist and one of the aforemen-
tioned concentrations of Aspirin. TLR and/or Aspirin
stimulation was for 24 hours, leading to a total incuba-
tion time of 48 hours. At the end of the 48 hours, super-
natants were collected and stored at −20C. The
experimental plate was washed with 1x Phosphate
Buffered Saline (PBS). 100μL 5% Metaphorphoric Acid
(MPA) was added to each experimental well, and the
plate was frozen at −80C.
MTT cell proliferation
Treatment toxicity was determined using a Non-
Radioactive Cell Proliferation Assay (Promega; Madison,
WI), following the manufacturer’s instructions. Briefly,
an experimental plate was set up following the guide-
lines outlined under ‘Experimental Setup #2’. Cells in
PBS were also plated as a positive control for necrosis.
At 24 hours post TLR and/or Aspirin stimulation, the
MTT cell proliferation assay was performed. 100μL of
supernatant was removed from the experimental plate,
leaving 150μL of supernatant in each well. Dye solution
(15μL) containing tetrazolium was added to each well
and the plate was incubated at 37C, 10% CO2 for
4 hours. During this incubation, tetrazolium salt in the
dye solution is converted to a formazan product by
living cells. After incubation, 100μL solubilization/stop
Solution was added to each well in order to solubilize
the formazan present in each well. The plate was
incubated for 1.5 hours at room temperature. Absorb-
ance values were determined at 570nm. Necrosis was
determined by comparing the treated wells to the
untreated wells. The student t-test was used to deter-
mine significance (p-values).
Total Glutathione production assay
Total Glutathione (tGSH) in activated EOC20 microglia
cells was measured colorimetrically using a Total Gluta-
thione (tGSH) Microplate Assay kit (Eagle Biosciences;
Boston, MA). Briefly, the experimental plate was washed
with 1x Phosphate Buffered Saline (PBS) after superna-
tants were collected. 100uL 5% Metaphosphoric Acid
(MPA) was added to each experimental well, and the
plate was frozen at −80C. The experiment plates were
then thawed at 37C. After the second freeze-thaw cycle,
the plate was put on ice for 15 minutes. After 15 min-
utes, 50μL of MPA extract was removed from each well
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standard curve was made following the manufacturer’s
instructions and added to the assay plate. Next,
5,5’-dithiobis(2-nitrobenzoic acid) [DTNB], Glutathione
oxidoreductase, and beta-Nicotinamide Adenine Di-
nucleotide Phosphate (β-NADPH) were added to each
well, allowing Glutathione to reduce DTNB and form a
mixed disulfide and a colored ion. This mixed disulfide
then reacted with Glutathione that is present in the
sample to form GSSG and another colored ion. GSSG
re-enters this cycle once it is reduced enzymatically. The
experimental plate was read at 405nm at 0 minutes and
10 minutes after the addition of β-NADPH. Absorbance
values were then used to determine the concentration of
total Glutathione (GSH and GSSG) that is present in the
sample. The sample values were normalized to the
untreated sample. Significance was determined using the
student t-test.
Pro-inflammatory cytokine assays
IL-6 and TNF-α secretion was determined using IL-6
and TNF-α Enzyme Linked Immunosorbent Assays
(ELISAs) (BD Falcon; San Diego, CA). Briefly, ELISA
plates were coated with IL-6 or TNF-α capture antibody
and incubated at 4C for 24 hours. The final concentra-
tion of the capture antibody was 1:250. After 24 hours,
the plate was washed with wash buffer that was made
following the manufacturer’s instructions. The plate was
then blocked for 1 hour at room temperature using
200μL assay diluent (10% FBS in PBS). Supernatants
collected from experimental setup #1 and #2 were
thawed and diluted 1:2. The diluted samples and an IL-6
or TNF-α standard curve were added to the plate after
the one hour blocking step and another round of wash-
ing. Sample and standard curve incubation was at room
temperature and lasted 2 hours. After another round of
washing, IL-6 or TNF-α Detection antibody (1:250) and
Streptavidin-Horse Radish Peroxidase Enzyme Reagent
(1:250) were added to each well and incubated for one
hour at room temperature. After incubating, the ELISA
plates were washed seven times using a plate shaker.
100μL TMB substrate solution containing Hydrogen
Peroxide and Tetramethylbenzidine (1:1) was added to
each well. The plate was incubated for 30 minutes in the
dark followed by an addition of 50 μL 2N sulfuric acid
and read at 450nm. Absorbance values were then used
to determine IL-6 and TNF-α secretion using the appro-
priate standard curve. Significance was determined using
the student t-test.
Total Nitric Oxide secretion assay
Total Nitric Oxide Secretion was determined using a
Total Nitric Oxide Assay Kit (Thermo Scientific;
Rockford, IL), following the manufacturer’s instructions.Briefly, supernatants collected from experimental setup
#1 and #2 were thawed and added to assay plates. A
Nitrate standard curve was also added to the experimen-
tal plate. Nicotinamide Adenine Dinucleotide Phosphate
(NADPH) and Nitrate Reductase were added to each
sample and standard. The plate was then incubated at
37C for 30 minutes, allowing Nitrate Reductase to func-
tion optimally and convert any Nitrate into
Nitrite. After the 30 minute incubation, Greiss Reagents
I and II were added to each sample. The plate was then
incubated for 10 minutes at room temperature, allowing
the Greiss Reagents to react with Nitrite and produce a
colored azo dye product. The plate was read at 540nm
and absorbance values for each sample were recorded.
The average absorbance of the blank was subtracted
from the absorbance values for each sample. The
samples were then normalized to the untreated sample.
Significance was determined using the student t-test,
p < 0.05 were considered statistically significant.
Abbreviations
DHA: Docosahexaenoic Acid; PUFA: Poly Unsaturated Fatty Acid;
NSAIDs: Non Steroidal Anti-Inflammatory; COX: Cyclooxygenase; tGSH: total
Glutathione; TLR: Toll Like Receptors; IL: Interleukin; TNF-α: Tumor Necrosis
Factor-alpha; NO: Nitric Oxide; ROS: Reactive Oxygen Species; Poly I:
C: Polyinosinic:polycytidylic.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LP carried out the majority of the experiments and manuscript preparation.
LP and EV had substantial contributions to conception, design, interpretation
of data. CV and JT carried out culturing and some experiments. All authors
read and approved the final manuscript.
Acknowledgements
This study was supported by a grant from the Research Corporation, Cottrell
College Science award and the Office of Research and Sponsored Programs
of Kean University.
Author details
1Kean University, 1000 Morris Avenue, Union, NJ, 07083, USA. 2Colfax
Oncology Center, 680 Broadway, Paterson, NJ 07514, USA.
Received: 10 January 2013 Accepted: 6 February 2013
Published: 11 February 2013
References
1. Przedborski S, Vila M, Jackson-Lewis V: Series introduction:
neurodegeneration: what is it and where are we? J Clin Invest 2003,
111:3–10.
2. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hon JS, Knapp DJ, Crews FT:
Systemic LPS causes chronic neuroinflammation and progressive
neurodegeneration. Glia 2007, 55:452–462.
3. Bal-Price A, Brown GC: Inflammatory neurodegeneration mediated by
nitric oxide from activated glia-inhibiting neuronal respiration, causing
glutamate release andexcitotoxicity. J Neurosci 2001, 31:6480–6491.
4. DeLegge MH, Smoke A: Neurodegeneration and inflammation. Nutr Clin
Pract 2008, 23:35–41.
5. Zhao W, Xie W, Le W, Beers DR, He Y, Henkel JS, Simpson EP, Yen AA, Xiao Q,
Appel SH: Activated microglia intitate motor neuron injury by a nitric oxide
and glutamate-mediated mechanism. J Neuropathol Exp Neurol 2004,
63:964–977.
Pettit et al. Lipids in Health and Disease 2013, 12:16 Page 14 of 14
http://www.lipidworld.com/content/12/1/166. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK: Activated microglia
mediate neuronal cell injury via a nitric oxide mechanism. J Immunol
1992, 149:2736–2741.
7. Lu DY, Tsao YY, Leung YM, Su KP: Docosahexaenoic acid
suppressesneuroinflammatory responses and induces heme oxygenase-I
expression in BV-2 microglia: implications of antidepressant effects for
omega-3 fatty acids. Neuropsychopharmacol 2010, 35:2238–2248.
8. Trudler D, Farfara D, Frenkel D: Toll-like receptor expression and signaling
in glia cells in neuro-amyloidogenic diseases: towards future therapeutic
applications. Mediat Inflamm 2010, 2010:1–12.
9. Blaylock RL: Chronic microglial activation and excitotoxicity secondary to
excessive immune stimulation: possible factors in gulf war syndrome
and autism. J Am Phys Sur 2004, 9:46–51.
10. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G: The link
between inflammation, synaptic transmission and neurodegeneration.
Cell Death Differ 2010, 17:1083–1091.
11. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y,
Mizuno T, Suzumura A: Tumor necrosis
factor-α induces neurotoxicity via glutamate release from hemichannels
of activated microglia in an autocrine manner. J Biol Chem 2006,
281:21362–21368.
12. Komatsu W, Ishihara K, Murata M, Saito H, Shinohara K: Docosahexaenoic
acid suppresses nitric oxide production and inducible nitric oxide
synthase expression in interferon-γ plus lipopolysaccharide-stimulated
murine macrophages by inhibiting oxidative stress. Free Radical Biol Med
2003, 34:1006–1016.
13. Narayanan BA, Narayanan NK, Simi B, Reddy BS: Modulation of inducible
nitric oxide synthase and related proinflammatory genes by the omega-
3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer
Res 2003, 63:972–979.
14. Bowling AC, Beal BF: Bioenergetic and oxidative stress in
neurodegenerative diseases. Life Sci 1995, 56:1151–1171.
15. Ajmone-Cat MA, Salvatori ML, De Simone R, Mancini M, Biagioni S, Bernardo
A, Cacci E, Minghetti L: Docosahexaenoic acid modulates inflammatory
and antineurogenic functions of activated microglial cells. J Neurosci Res
2011, 90:1–13.
16. Serhan CN, Fredman G, Yang R, Karamnov S, Belayev LS, Bazan NG, Zhu M,
Winkler JW, Petasis NA: Novel proresolving aspirin-triggered DHA
pathway. Chem Biol 2011, 18(8):976–987.
17. Calon F, Cole G: Neuroprotective action of omega-3 polyunsaturated
fatty acids against neurodegnerative diseases: evidence from animal
studies. Prostag Leukotr Ess 2007, 77:287–293.
18. Palacios-Pelaez R, Lukiw WJ, Bazan NG: Omega-3 essential fatty acids
modulate initiation and progression of neurodegenerative disease.
Mol Neurobiol 2010, 41:367–374.
19. Bazan NG: The onset of brain injury and neurodegeneration triggers the
synthesis of docosanoid neuroprotective signaling. Cell Mol Bio 2006,
26:901–913.
20. Olson JK, Miller SD: Microglia initiate central nervous system innate and
adaptive immune responses through multiple TLRs. J Immunol 2004,
173:3916–3924.
21. Zhu Y, Carvey PM, Ling Z: Altered glutathione homeostasis in animals
prenatally exposed to lipopolysaccharide. Neurochem Int 2007,
50:671–680.
22. Leonardi F, Attorri L, Di Benedetto R, Di Biase A, Sanchez M, Pellizzari
Tregno F, Nardini M, Salvati S: Docosahexaenoic acid supplementation
induces dose and time dependent oxidative changes in C6 glioma cells.
Free Radic Res 2007, 41:748–756.
23. Cole GM, Morihara T, Lim GP, Yang FF, Begum A, Frautschy SA: NSAID and
antioxidant prevention of Alzheimer’s disease. Ann NY Acad Sci 2004,
1034:68–84.
24. Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME,
Frautschy SA: Prevention of Alzheimer’s disease: omega-3 fatty acid and
phenolic anti-oxidant interventions. Neurobiol Aging 2005, 26S:S133–S136.
25. Laye S: Polyunsaturated fatty acids, neuroinflammation and well being.
Prostag Leukotr Ess 2010, 82:295–303.
26. Asanuma M, Miyazaki I, Ogawa N: Neuroprotective effects of nonsteroidal
anti- inflammatory drugs on neurodegenerative diseases. Curr Pharm Des
2004, 10:695–700.27. Lleo A, Galea E, Sastre M: Molecular targets of non-steroidal anti-
inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 2007,
64:1403–1418.
28. Klegeris A, McGeer PL: Non-steroidal anti-inflammatory drugs (NSAIDs)
and other anti-inflammatory agents in the treatment of
neurodegenerative disease. Curr Alzheimer Res 2005, 2:355–365.
doi:10.1186/1476-511X-12-16
Cite this article as: Pettit et al.: Modulating the inflammatory properties
of activated microglia with Docosahexaenoic acid and Aspirin. Lipids in
Health and Disease 2013 12:16.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
